Kuo, C.-T.C.-T.KuoWang, J.-Y.J.-Y.WangLu, S.-R.S.-R.LuLai, Y.-S.Y.-S.LaiHSIU-HAO CHANGHsieh, J.-T.J.-T.HsiehWo, A.M.A.M.WoChen, B.P.C.B.P.C.ChenLu, J.-H.J.-H.LuANDREW WOHSIN-YU LEE2020-12-182020-12-1820192045-2322https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069005490&doi=10.1038%2fs41598-019-46502-3&partnerID=40&md5=2d4003669938463d02044ba96b3b40eahttps://scholars.lib.ntu.edu.tw/handle/123456789/527814Therapeutic drug synergism intervened in cancer treatments has been demonstrated to be more effective than using a single effector. However, it remains inherently challenging, with a limited cell count from tumor samples, to achieve potent personalized drug cocktails. To address the issue above, we herein present a nanodroplet cell processing platform. The platform incorporates an automatic nanodroplet dispenser with cell array ParaStamp chips, which were fabricated by a new wax stamping approach derived from laser direct writing. Such approach enables not only the on-demand de-wetting with hydrophobic wax films on substrates but also the mask-less fabrication of non-planar microstructures (i.e. no photolithography process). The ParaStamp chip was pre-occupied with anti-cancer drugs and their associate mixtures, enabling for the spatially addressable screening of optimal drug combinations simultaneously. Each droplet with a critical volume of 200 nl containing with 100 cells was utilized. Results revealed that the optimal combination reduces approximate 28-folds of conducted doses compared with single drugs. Tumor inhibition with the optimally selected drug combination was further confirmed by using PC-3 tumor-bearing mouse models. Together, the nanodroplet cell processing platform could therefore offer new opportunities to power the personalized cancer medicine at early-stage drug screening and discovery. ? 2019, The Author(s).[SDGs]SDG3antineoplastic agent; baysilon; dimeticone; animal; devices; drug potentiation; drug screening; equipment design; high throughput screening; human; laser; male; miniaturization; nude mouse; procedures; Animals; Antineoplastic Combined Chemotherapy Protocols; Dimethylpolysiloxanes; Drug Screening Assays, Antitumor; Drug Synergism; Equipment Design; High-Throughput Screening Assays; Humans; Lasers; Male; Mice, Nude; Miniaturization; PC-3 Cells; Xenograft Model Antitumor Assaysjournal article10.1038/s41598-019-46502-3313007422-s2.0-85069005490